Symbio Pharmaceuticals Limited (JP:4582)
:4582
Want to see JP:4582 full AI Analyst Report?
4582 Stock Chart & Stats
¥90.00
¥6.00(2.96%)
At close: 4:00 PM EST
¥90.00
¥6.00(2.96%)
Day’s Range― - ―
52-Week Range¥68.00 - ¥229.00
Previous CloseN/A
Volume447.50K
Average Volume (3M)577.10K
Market Cap
¥5.41B
Enterprise Value¥3.43B
Total Cash (Recent Filing)¥3.05B
Total Debt (Recent Filing)¥1.30B
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-100.12
Shares Outstanding76,352,486
10 Day Avg. Volume434,010
30 Day Avg. Volume577,100
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialty Licensing Business ModelSymbio’s in‑licensing and partnering model spreads development cost and risk across originators and commercialization partners. Durable revenue streams from milestones, royalties and partner commercialization reduce capital intensity and allow pipeline exposure without sole funding burden, supporting strategy over months.
High Gross MarginSustained high gross margins indicate core product economics and pricing power in specialty segments. Over 2–6 months this supports potential profitability if operating cost control or partner commercialization reduces SG&A/R&D burden, making margins a structural strength once fixed costs are managed.
Meaningful Asset BaseA tangible asset base provides collateral and operational capacity for manufacturing, inventory or licensing agreements. This structural asset support enhances financing options and bargaining power with partners, improving resilience over a multi‑month horizon even as earnings recover are required to restore equity.
Bears Say
Sustained Revenue DeclineMulti‑year top‑line decline weakens scale economics and partner confidence, reducing internal funds for trials and marketing. Over 2–6 months continued revenue erosion can limit ability to invest in commercial launches or sustain milestone payments, pressuring long‑term development and growth plans.
Negative Operating Cash FlowPersistent negative cash generation forces reliance on external financing and may constrain R&D and launch activities. Over the medium term, continued cash burn raises liquidity and refinancing risk, potentially forcing dilutive capital raises or curtailed programs if operating performance doesn’t improve.
Rising Leverage And Compressed EquityLeverage above equity and eroded equity reduce financial flexibility and increase interest burden. Structurally, higher debt amplifies downside in adverse scenarios and limits capacity for opportunistic licensing or acquisitions over months, making recovery harder without meaningful earnings improvement.
Symbio Pharmaceuticals Limited News
4582 FAQ
What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?
Symbio Pharmaceuticals Limited lowest stock price was ¥68.00 and its highest was ¥229.00 in the past 12 months.
What is Symbio Pharmaceuticals Limited’s market cap?
Symbio Pharmaceuticals Limited’s market cap is ¥5.41B.
When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?
Symbio Pharmaceuticals Limited’s upcoming earnings report date is Jul 30, 2026 which is in 48 days.
How were Symbio Pharmaceuticals Limited’s earnings last quarter?
Symbio Pharmaceuticals Limited released its earnings results on May 07, 2026. The company reported -¥35.89 earnings per share for the quarter, missing the consensus estimate of N/A by -¥35.89.
Is Symbio Pharmaceuticals Limited overvalued?
According to Wall Street analysts Symbio Pharmaceuticals Limited’s price is currently Overvalued.
Does Symbio Pharmaceuticals Limited pay dividends?
Symbio Pharmaceuticals Limited does not currently pay dividends.
What is Symbio Pharmaceuticals Limited’s EPS estimate?
Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Symbio Pharmaceuticals Limited have?
Symbio Pharmaceuticals Limited has 76,352,486 shares outstanding.
What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?
Symbio Pharmaceuticals Limited reported an EPS of -¥35.89 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in JP:4582
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited, established in 2005 and headquartered in Tokyo, Japan, is a pharmaceutical company focused on the research, development, production, and commercialization of medicinal products, primarily within the oncology and hematology fields for the Japanese market. The company's leading marketed anti-cancer drug is TREAKISYM (SyB L-0501), utilized for treating non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia. TREAKISYM is also currently undergoing Phase III clinical trials for relapsed/refractory diffuse large B-cell lymphoma. SymBio's development pipeline includes enhanced formulations of this drug: SyB L-1701, a ready-to-dilute version, and SyB L-1702, designed for rapid infusion. Beyond its cancer treatments, the company is advancing SyB L-1101, an intravenous formulation in Phase III trials for higher-risk myelodysplastic syndromes (HR-MDS), as well as SyB C-1101, an oral formulation in Phase II/III trials, combined with Azacitidine, also for HR-MDS. Additionally, SymBio is developing SyB V-1901, an antiviral medication targeting infectious diseases.
Technical Analysis
Solasia Pharma KK
―
Wakamoto Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Medrx Co., Ltd.
―